Otsuka Pharmaceutical Europe Ltd. (Otsuka) and H. Lundbeck A/S (Lundbeck) today announced that the European Commission (EC) has approved Rxulti® (brexpiprazole) for the treatment of schizophrenia in ...
Lundbeck A/S (Lundbeck) today announced that the European Commission (EC) has approved Rxulti ® (brexpiprazole) for the treatment of schizophrenia in adolescents aged 13 years and older. 1 ...
Otsuka Pharmaceutical Europe and Lundbeck have announced that the European Commission has approved Rxulti (brexpiprazole) for ...
Brexpiprazole's indication for the treatment of schizophrenia in adults is extended to include adolescents aged 13 years and older 1 Approval follows a positive Committee for Medicinal Products ...
The European Commission (EC) has approved Danish CNS specialist Lundbeck (LUND: CO) and Otsuka Europe’s Rxulti ...
Axsome's AXS-05 shows strong efficacy in treating Alzheimer's Disease Agitation, with significant CMAI score reductions.
Verywell Health on MSN3d
7 Medications for Dementia and Alzhiemer's DiseaseMedication options are available to help manage the cognitive and behavioral symptoms of dementia and Alzheimer's disease.
Vadodara: Alembic Global Holding SA, a wholly owned subsidiary of Alembic Pharmaceuticals Limited has incorporated a wholly-owned subsidiary in USA, named Alembic Lifesciences Inc.
CMPS earnings call for the period ending December 31, 2024. Compass Pathways Plc ( CMPS 7.30%) Q4 2024 Earnings Call Feb 27, 2025, 8:00 a.m. ET ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback